ReviewClinical and translational radiation oncology2026
Reirradiation for locally recurrent soft tissue sarcomas: A systematic review.
Review in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimising Clinical Outcomes Following R1 Resection in Soft Tissue Sarcoma: An Evidence-Based Approach.Current treatment options in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Locally recurrent soft tissue sarcomas (LRSTS) present a significant clinical challenge.There are major limitations to secondary treatment modalities. Reirradiation in such cases has traditionally been considered contraindicated due to the risk of severe normal tissue toxicity. On the other hand, there is evidence showing that multimodality salvage treatment can improve outcomes in some patients. The objective of this systematic review is to determine the feasibility of reirradiation in LRSTS. This systematic review included clinical studies that presented outcomes of patients who underwent any form of repeated radiation treatment for LRSTS. Authors used PubMed Medline, Embase and Scopus databases. This review follows the PRISMA guidelines. The search and selection identified 20 studies involving reirradiation for LRSTS, encompassing a total of 437 patients. Reirradiation modalities comprised brachytherapy, intraoperative radiotherapy (RT), external-beam RT, carbon ion RT and proton RT, as either definitive or perioperative treatment. Reirradiation doses varied across studies, with cumulative nominal doses exceeding 100 Gy in some cohorts. Local control rates ranged from 15 % to 100 %, with most studies reporting the range of 50-70 %. Overall survival rates were similarly variable. Acute and late toxicities were significant, with grade ≥3 complications reported in up to 50 % of patients. The analysis showed that reirradiation, both definitive or as a part of multimodality treatment, can be used in selected patients with LRSTS. This review is limited by retrospective study designs, and a large heterogeneity in patient populations and treatment regimens. Further quality investigation is needed to clearly determine the indications for reirradiation in LRSTS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.